DiaMedica Therapeutics Inc
NASDAQ:DMAC
DiaMedica Therapeutics Inc
Other Items
DiaMedica Therapeutics Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Other Items
-$4.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.9B
|
CAGR 3-Years
-108%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$1.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$691.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
See Also
What is DiaMedica Therapeutics Inc's Other Items?
Other Items
-4.9m
USD
Based on the financial report for Sep 30, 2025, DiaMedica Therapeutics Inc's Other Items amounts to -4.9m USD.
What is DiaMedica Therapeutics Inc's Other Items growth rate?
Other Items CAGR 5Y
21%
The average annual Other Items growth rates for DiaMedica Therapeutics Inc have been -40% over the past three years , 21% over the past five years .
